Introduction {#sec1-0300060518803232}
============

In 2012, there were an estimated 782,500 new cases of liver cancer and more than 745,500 deaths due to the disease worldwide; more than 50% of these deaths occurred in China.^[@bibr1-0300060518803232]^ Most primary liver cancers (70%--90%) are hepatocellular carcinoma (HCC); notably, HCC is the third leading cause of cancer death in China, and was responsible for more than 400,000 deaths in 2015.^[@bibr2-0300060518803232]^ Although multiple risk factors for HCC have been identified, including chemical and viral exposure, it remains a particularly lethal disease because it is typically asymptomatic prior to reaching the terminal stage. Serum alpha-fetoprotein (AFP) is commonly used as a biomarker for HCC; however, it demonstrates low sensitivity and specificity. Moreover, its level varies with the tumor type and patient population. There is thus a critical need to identify alternative diagnostic and prognostic markers for HCC.

Spondin-2 (SPON2) is a secreted extracellular matrix protein and a member of the Mindin/F-Spondin family.^[@bibr3-0300060518803232]^ SPON2 has multiple functions in a variety of crucial cellular processes, including development of neurons, recruitment of inflammatory cells, and activation of the innate immune response.^[@bibr4-0300060518803232],[@bibr5-0300060518803232]^ Recently, *SPON2* overexpression was found in HCC,^[@bibr6-0300060518803232][@bibr7-0300060518803232]--[@bibr8-0300060518803232]^ colorectal carcinoma,^[@bibr9-0300060518803232][@bibr10-0300060518803232]--[@bibr11-0300060518803232]^ gastric cancer,^[@bibr12-0300060518803232],[@bibr13-0300060518803232]^ Barrett's adenocarcinoma,^[@bibr14-0300060518803232]^ prostate cancer,^[@bibr15-0300060518803232][@bibr16-0300060518803232][@bibr17-0300060518803232][@bibr18-0300060518803232][@bibr19-0300060518803232]--[@bibr20-0300060518803232]^ ovarian cancer,^[@bibr21-0300060518803232],[@bibr22-0300060518803232]^ pancreatic cancer,^[@bibr23-0300060518803232]^ pulmonary adenocarcinoma,^[@bibr24-0300060518803232]^ and breast cancer.^[@bibr25-0300060518803232]^ In addition, *SPON2* has been proposed as a new serum and histological diagnostic biomarker, as well as an independent prognostic indicator for colorectal carcinoma,^[@bibr10-0300060518803232],[@bibr11-0300060518803232]^ gastric cancer,^[@bibr13-0300060518803232]^ prostate cancer,^[@bibr17-0300060518803232],[@bibr19-0300060518803232],[@bibr20-0300060518803232]^ and ovarian cancer.^[@bibr21-0300060518803232],[@bibr22-0300060518803232]^

SPON2 expression is elevated in HCC tumor tissues, compared with matched non-cancerous liver tissue.^[@bibr6-0300060518803232][@bibr7-0300060518803232]--[@bibr8-0300060518803232]^ Zhang et al.^[@bibr8-0300060518803232]^ reported that HCC patients with upregulated SPON2 expression had better overall survival (OS). However, an inverse relationship between SPON2 expression and OS has been found in other inflammatory tumors, such as colorectal carcinoma^[@bibr10-0300060518803232],[@bibr11-0300060518803232]^ and gastric cancer.^[@bibr13-0300060518803232]^ Therefore, the relationship between SPON2 expression and prognosis in HCC remains unclear. The purpose of the present study was to assess expression of *SPON2* mRNA and SPON2 protein in HCC and determine its association with clinicopathological features and patient prognosis.

Materials and methods {#sec2-0300060518803232}
=====================

Patients and tissue samples {#sec3-0300060518803232}
---------------------------

Two sets of patient samples were evaluated. We obtained HCC and matched non-cancerous liver tissue from 20 HCC patients undergoing curative resection at Affiliated Hospital of Nantong University (Jiangsu, China) from June 2013 to June 2014. These samples were used to analyze *SPON2* mRNA expression by quantitative reverse transcription-polymerase chain reaction (qRT-PCR). We also obtained matched tumor and normal liver tissue samples from 107 HCC patients undergoing curative resection at the same hospital between January 2004 and December 2009; these tissues were used to construct tissue microarrays (TMA) for immunohistochemical (IHC) analysis of SPON2 protein. All patients had pathologically confirmed HCC; none had undergone chemotherapy, radiation therapy, or immunotherapy prior to curative surgical resection. Post-surgical follow-ups were completed by December 2014 (median follow-up 39 months, range 1--85 months). Clinicopathological data were collected from medical records during the inpatient stay and included sex, age, differentiation grade, tumor diameter, Child-Pugh stage, hepatocirrhosis status, hepatitis B virus (HBV) infection, tumor thrombus, AFP level, Barcelona Clinic Liver Cancer (BCLC) stage, envelope invasion, and tumor satellite lesions. All patients provided written informed consent before surgery, and the study protocol was approved by the Human Research Ethics Committee of Affiliated Hospital of Nantong University.

RNA extraction and qRT-PCR {#sec4-0300060518803232}
--------------------------

Total RNA was extracted from the 20 paired HCC and matched non-cancerous liver tissue samples by using TRIzol reagent (Invitrogen, Karlsruhe, Germany). One-step qRT-PCR analysis was performed on an Applied Biosystems 7500 Real-Time PCR System by using the LightCycler FastStart DNA Master SYBR Green I Kit (Roche Diagnostics, Tokyo, Japan). The SPON2 primers were as follows: forward 5′-AAGAACCAGTACGTCAGTAACGG-3′ and reverse 5′-CACAAACGAGACCAGCGAGT-3′ (201-bp). Glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) was amplified to normalize the *SPON2* mRNA levels (*GAPDH* forward primer 5′-AGAAGGCTGGGGCTCATTTG-3′ and reverse primer 5′-AGGGGCCATCCACATCTTC-3′). The reverse transcription conditions were 42°C for 60 minutes and 70°C for 5 minutes. The PCR conditions were 10 minutes at 95°C, followed by 40 cycles of 15 s at 95°C, 30 s at 60°C, and 30 s at 72°C. All reactions were performed in quadruplicate.

TMA-IHC {#sec5-0300060518803232}
-------

TMA construction and IHC staining were performed as previously described.^[@bibr26-0300060518803232],[@bibr27-0300060518803232]^ The anti-SPON2 primary antibody was from Affinity (\#DF4682, China). Immunostaining levels were evaluated independently by two investigators who were blinded to the sample identities. The staining intensity was scored as: 0 (−, no staining), 1 (+, weak staining), 2 (++, moderate staining), or 3 (+++, strong staining). The proportion of cells staining positive for SPON2 was also recorded. The product of the intensity score and percentage positive cells was recorded as the final SPON2 staining score (range 0--300). For analysis, samples were classified as "low" or "high" SPON2 protein expression based on a cutoff point of 100, which was identified by using X-tile software (Rimm Laboratory, Yale University, New Haven, CT, USA) as described previously.^[@bibr28-0300060518803232]^ Scores of 0 to 100 and 101 to 300 were considered low and high expression, respectively.

Bioinformatic analysis of the Oncomine database {#sec6-0300060518803232}
-----------------------------------------------

Datasets of *SPON2* mRNA expression in normal and diseased liver tissues were obtained from the Oncomine database (<http://www.oncomine.org/resource/login.html>) as described elsewhere.^[@bibr11-0300060518803232]^ "SPON2," "Hepatocellular Carcinoma," "mRNA," and "Cancer vs Normal Analysis" filters were applied as the search terms to compare *SPON2* mRNA expression level between HCC and other liver tissues. "Survival Status" was applied as an additional filter to evaluate the association between expression and survival. "SPON2," "Hepatocellular Carcinoma," and "mRNA" filters were applied to evaluate the correlation between expression and clinicopathological parameters. *SPON2* mRNA expression levels were further classified into greater than or less than the median groups according to the log^[@bibr2-0300060518803232]^ median-centered intensity value obtained with Microsoft Excel.

Statistical analysis {#sec7-0300060518803232}
--------------------

Statistical analysis was performed by using SPSS version 24.0 software (IBM Corp., Armonk, NY, USA) and Prism 6.01 software (GraphPad, La Jolla, CA, USA). Student's t-test was used to evaluate differences in *SPON2* mRNA expression levels. The relationships between *SPON2* mRNA or SPON2 protein expression and clinicopathological parameters were analyzed by using χ^2^ tests. Kaplan-Meier curves and the log-rank test were used to evaluate survival. Features verified to have statistically significant prognostic value in a univariate Cox regression model were then entered into a multivariate Cox regression model. Differences were regarded as statistically significant at *P*\<0.05.

Results {#sec8-0300060518803232}
=======

Upregulation of SPON2 mRNA expression in HCC tissues {#sec9-0300060518803232}
----------------------------------------------------

To assess whether *SPON2* is differentially expressed in HCC and normal liver tissues at the mRNA level, we analyzed datasets obtained from the Oncomine database. *SPON2* mRNA levels were significantly higher in HCC tissues, compared with non-cancerous liver tissues, in the Roessler Liver dataset (n=22, *P*\<0.0001; [Figure 1a](#fig1-0300060518803232){ref-type="fig"}), Roessler Liver 2 dataset (n=225, *P*\<0.0001; [Figure 1b](#fig1-0300060518803232){ref-type="fig"}), and Wurmbach Liver dataset (n=35, *P*=0.0003; [Figure 1c](#fig1-0300060518803232){ref-type="fig"}). The Mas Liver dataset ([Figure 1d](#fig1-0300060518803232){ref-type="fig"}) showed no difference in *SPON2* mRNA between normal and cirrhotic liver samples (n=58, *P*=0.1838) or between cirrhotic and HCC samples (n=38, *P*=0.0897); however, *SPON2* mRNA was significantly upregulated in HCC tissues, compared with normal liver (n=38, *P*=0.0209). These analyses of a total of 320 HCC samples and 270 non-cancerous liver control samples indicated that *SPON2* mRNA expression is increased in HCC. To confirm this result, we performed qRT-PCR analysis of *SPON2* mRNA expression in tissues obtained from 20 HCC patients in our local population; *SPON2* mRNA was significantly higher in HCC tissues, compared with matched non-cancerous liver tissues (n=20, *P*\<0.0001; [Figure 2a](#fig2-0300060518803232){ref-type="fig"}).

![Mining of the Oncomine database indicates that *SPON2* mRNA expression is upregulated in HCC tissues. (a--c) *SPON2* mRNA expression in normal liver and HCC tissues, based on the Roessler Liver dataset (a), Roessler Liver 2 dataset (b), and Wurmbach Liver dataset (c). (d) *SPON2* mRNA expression in normal liver, cirrhotic liver, and HCC tissues, based on the Mas Liver dataset.](10.1177_0300060518803232-fig1){#fig1-0300060518803232}

![Expression of SPON2 in HCC and normal liver tissue. (a) qRT-PCR analysis of *SPON2* mRNA expression in 20 paired HCC and matched non-cancerous liver tissues. (b) TMA-IHC analysis of SPON2 protein expression in 107 paired HCC and matched non-cancerous liver tissues.](10.1177_0300060518803232-fig2){#fig2-0300060518803232}

Upregulation of SPON2 protein expression in HCC tissues {#sec10-0300060518803232}
-------------------------------------------------------

Next, we analyzed SPON2 protein expression by IHC staining of a TMA composed of 107 paired HCC and matched non-cancerous liver tissues. As shown in [Figure 2b](#fig2-0300060518803232){ref-type="fig"}, SPON2 protein was primarily detected in the cytoplasm of HCC cells. Notably, SPON2 protein expression was detected in a significantly greater number of samples from HCC tissues (56/107, 52.336%) than from matched non-cancerous liver tissues (21/107, 19.626%; *P*\<0.0001), Therefore, upregulated expression of SPON2 appears to be associated with development of HCC.

Association between upregulated SPON2 expression and clinicopathological parameters in HCC patients {#sec11-0300060518803232}
---------------------------------------------------------------------------------------------------

To assess the association between *SPON2* mRNA expression and clinicopathological parameters of HCC patients, we analyzed the Wurmbach Liver, Jia Liver, and Chiang Liver datasets in the Oncomine database. Each dataset was divided into high and low *SPON2* expression groups based on the median *SPON2* mRNA level. We found that the *SPON2* mRNA level was significantly associated with tumor size in the Wurmbach Liver dataset (χ^2^=4.309, *P*=0.038) and with age in both the Jia Liver (χ^2^=5.069, *P*=0.014) and Chiang Liver (χ^2^=5.199, *P*=0.023) datasets ([Table 1](#table1-0300060518803232){ref-type="table"}). Analysis of the TMA-IHC data revealed associations between the SPON2 protein level and differentiation grade (χ^2^=12.914, *P*=0.002), tumor diameter (χ^2^=4.809, *P*=0.028), and Child-Pugh stage (χ^2^=10.178, *P*=0.001) ([Table 2](#table2-0300060518803232){ref-type="table"}). However, other clinical features, including sex, age, hepatocirrhosis status, HBV infection, tumor thrombus, AFP level, BCLC stage, envelope invasion, and tumor satellite lesions, were not significantly correlated with SPON2 protein expression. Taken together, these findings demonstrate that the increase in SPON2 expression in HCC was related to tumor size.

###### 

Association between *SPON2* mRNA expression and clinicopathological parameters in HCC patients based on Oncomine datasets.

![](10.1177_0300060518803232-table1)

  Dataset^[a](#table-fn1-0300060518803232){ref-type="table-fn"}^   Clinicopathological parameters   n     *SPON2* expression   χ^2^   *P* value   
  ---------------------------------------------------------------- -------------------------------- ----- -------------------- ------ ----------- -------
  Wurmbach Liver                                                                                                                                  
                                                                   Size (cm)                                                                      
                                                                    ≤5                              23    11                   12     4.309       0.038
                                                                    \>5                             10    1                    9                  
  Chiang Liver                                                                                                                                    
                                                                   Age (years)                                                                    
                                                                    ≤50                             5     0                    5      5.199       0.023
                                                                    \>50                            76    40                   36                 
  Jia Liver                                                                                                                                       
                                                                   Age (years)                                                                    
                                                                    ≤50                             121   51                   70     5.069       0.014
                                                                    \>50                            117   68                   49                 

The analysis was performed by using datasets from the Oncomine cancer gene expression microarray database (<https://www.oncomine.org/resource/login.html>).

###### 

Association between SPON2 protein expression and clinicopathological parameters in HCC patients based on TMA-IHC analysis.

![](10.1177_0300060518803232-table2)

  Clinicopathological parameters   n    Low expression   High expression   χ^2^     *P* value
  -------------------------------- ---- ---------------- ----------------- -------- -------------------------------------------------------------
  Sex                                                                               
   Male                            75   35               40                0.100    0.752
   Female                          32   16               16                         
  Age (years)                                                                       
   ≤50                             45   22               23                0.047    0.829
   \>50                            62   29               33                         
  Grade of differentiation                                                          
   Low                             39   26               13                12.914   0.002[\*](#table-fn2-0300060518803232){ref-type="table-fn"}
   Middle                          35   17               18                         
   High                            33   8                25                         
  Tumor diameter (cm)                                                               
   ≤5                              49   29               20                4.809    0.028[\*](#table-fn2-0300060518803232){ref-type="table-fn"}
   \>5                             58   22               36                         
  Child-Pugh stage                                                                  
   A                               38   26               12                10.178   0.001[\*](#table-fn2-0300060518803232){ref-type="table-fn"}
   B or C                          69   25               44                         
  Hepatocirrhosis                                                                   
   Absent                          24   11               13                0.042    0.838
   Present                         83   40               43                         
  HBV infection                                                                     
   Absent                          41   21               20                0.337    0.562
   Present                         66   30               36                         
  Tumor thrombus                                                                    
   Absent                          47   25               22                1.027    0.311
   Present                         60   26               34                         
  AFP (ng/mL)                                                                       
   ≤20                             52   27               25                0.736    0.391
   \>20                            55   24               31                         
  BCLC stage                                                                        
   A                               24   14               10                1.412    0.235
   B, C, or D                      83   37               46                         
  Envelope                                                                          
   Absent                          63   26               37                2.511    0.113
   Present                         44   25               19                         
  Tumor satellite                                                                   
   Absent                          58   26               32                0.408    0.523
   Present                         49   25               24                         

\**P*\<0.05; Serum Alpha-Fetoprotein (AFP); Hepatitis B Virus (HBV); Barcelona Clinic Liver Cancer (BCLC).

Association between upregulated SPON2 expression and OS in HCC {#sec12-0300060518803232}
--------------------------------------------------------------

To determine whether *SPON2* mRNA expression correlated with OS in HCC patients, we performed a Kaplan-Meier survival analysis. Using the Hoshida Liver Statistics dataset (n=118, including 80 completed and 38 censored cases) in the Oncomine database, no relationship could be detected between *SPON2* mRNA expression and prognosis (log-rank test=1.399, *P*=0.2368; [Figure 3a](#fig3-0300060518803232){ref-type="fig"}). However, when the analysis was performed using the TMA-IHC dataset, high SPON2 protein expression in the cytoplasm of HCC cells correlated significantly with poor prognosis (log-rank test=4.381, *P*=0.036; [Figure 3b](#fig3-0300060518803232){ref-type="fig"}). These results suggest that the level of SPON2 protein in tumor tissue could be a prognostic indicator in HCC.

![Kaplan-Meier survival analysis of SPON2 expression in HCC patients. Correlation between prognosis of HCC patients and tumor expression of (a) *SPON2* mRNA, based on the Oncomine Hoshida Liver Statistics dataset, and (b) SPON2 protein, based on the TMA-IHC dataset.](10.1177_0300060518803232-fig3){#fig3-0300060518803232}

SPON2 protein expression level as a prognostic predictor in HCC {#sec13-0300060518803232}
---------------------------------------------------------------

We performed univariate and multivariate Cox regression analyses of SPON2 protein expression and clinicopathological parameters in the TMA-IHC dataset to identify potential predictors of OS and disease-free survival (DFS) in HCC patients. Univariate analyses indicated that tumor thrombus, BCLC stage, and SPON2 protein expression were significantly associated with OS and DFS in HCC patients ([Table 3](#table3-0300060518803232){ref-type="table"}). When these factors were included in a multivariate Cox regression model, tumor thrombus and SPON2 protein expression remained independent prognostic predictors for HCC ([Table 3](#table3-0300060518803232){ref-type="table"}).

###### 

Univariate and multivariate analysis of overall survival and disease-free survival in HCC patients.

![](10.1177_0300060518803232-table3)

  Characteristics            Overall Survival       Disease-Free Survival                                                                                                 
  -------------------------- ---------------------- ----------------------- ---------------------- ----------- ----------------------- ----------- ---------------------- -----------
  Sex                                                                                                                                                                     
   Male vs. female           1.037 (0.499--2.151)   0.932                                                      0.890 (0.428--1.847)    0.754                              
  Age (year)                                                                                                                                                              
   ≤50 vs. \>50              0.811 (0.367--1.791)   0.604                                                      0.592 (0.275--1.275)    0.180                              
  Grade of differentiation                                                                                                                                                
   Low/Middle/High           0.764 (0.372--1.573)   0.466                                                      0.581 (0.290--1.166)    0.127                              
  Tumor diameter (cm)                                                                                                                                                     
   ≤5 vs. \>5                1.639 (0.460--5.836)   0.446                                                      2.967 (0.742--11.856)   0.124                              
  Child-Pugh stage                                                                                                                                                        
   A vs. B or C              0.874 (0.170--4.503)   0.872                                                      1.180 (0.370--3.766)    0.780                              
  Hepatocirrhosis                                                                                                                                                         
   − vs. +                   1.896 (0.789--4.556)   0.153                                                      2.264 (0.950--5.397)    0.065                              
  HBV infection                                                                                                                                                           
   − vs. +                   1.541 (0.778--3.052)   0.215                                                      1.359 (0.700--2.638)    0.365                              
  Tumor thrombus                                                                                                                                                          
   − vs. +                   2.400 (1.219--4.726)   0.011\*                 2.372 (1.264--4.452)   0.007\*     2.123 (1.086--4.153)    0.028\*     2.079 (1.113--3.884)   0.022\*
  AFP (ng/mL)                                                                                                                                                             
   ≤20 vs. \>20              1.369 (0.717--2.613)   0.341                                                      1.735 (0.905--3.324)    0.097                              
  BCLC stage                                                                                                                                                              
   A vs. B, C, or D          0.367 (0.154--0.879)   0.024\*                 1.053 (0.515--0.252)   0.069       0.398 (0.167--0.951)    0.038\*     0.681 (0.340--1.363)   0.278
  Envelope                                                                                                                                                                
   − vs. +                   0.637 (0.189--2.150)   0.467                                                      0.394 (0.103--1.506)    0.173                              
  Tumor satellite                                                                                                                                                         
   − vs. +                   1.829 (0.924--3.622)   0.083                                                      1.797 (0.920--3.510)    0.086                              
  SPON2 expression                                                                                                                                                        
   Low vs. High              4.519 (2.142--9.533)   \<0.001\*               3.093 (1.659--5.766)   \<0.001\*   4.330 (2.056--9.121)    \<0.001\*   3.175 (1.692--5.960)   \<0.001\*

\**P*\<0.05; Serum Alpha-Fetoprotein (AFP); Hepatitis B Virus (HBV); Barcelona Clinic Liver Cancer (BCLC); Hazard Ratio (HR); Confidence Interval (CI).

Discussion {#sec14-0300060518803232}
==========

In this study, we evaluated a total of 320 cancer samples and 270 normal liver controls from four independent datasets in the Oncomine database; we determined that *SPON2* mRNA expression is upregulated in HCC, compared with normal liver tissue. We verified these results by qRT-PCR analysis of 20 paired HCC and matched non-cancerous tissue samples from our local patient population. Furthermore, we examined SPON2 protein expression levels by TMA-IHC analysis of 107 HCC and matched non-cancerous liver tissues, which demonstrated that SPON2 protein levels were significantly elevated in HCC tissues, compared with normal liver tissue; this result is consistent with previous findings.^[@bibr7-0300060518803232],[@bibr8-0300060518803232]^ Collectively, our results support an association between increased SPON2 expression and HCC carcinogenesis and/or malignancy.

Recently, Zhang et al.^[@bibr8-0300060518803232]^ reported that SPON2 expression in HCC tissues was closely correlated with vascular invasion and tumor-node-metastasis stage. In the current study, we found that SPON2 protein expression correlated with differentiation grade, tumor diameter, and Child-Pugh stage. Tumor size is an important predictor of vascular invasion. SPON2 is thought to promote viability, migration, invasion, and colony formation in colorectal carcinoma cells.^[@bibr10-0300060518803232]^ However, overexpression of SPON2 inhibits the migration and invasion abilities of HCC cell lines.^[@bibr7-0300060518803232],[@bibr8-0300060518803232]^ These conflicting findings suggest that the role of SPON2 in cell migration and invasion is complex.

Tumors with limited invasive abilities are typically associated with better prognosis. Elevated SPON2 expression has been established as a prognostic biomarker for some inflammatory tumors, such as gastric cancer and colorectal carcinoma.^[@bibr9-0300060518803232][@bibr10-0300060518803232]--[@bibr11-0300060518803232],[@bibr13-0300060518803232]^ However, the utility of SPON2 as a prognostic biomarker in HCC is unclear. In the current study, Kaplan-Meier analysis revealed that HCC patients with higher SPON2 protein expression had significantly worse OS, compared with patients with lower tumor protein expression; this suggested that SPON2 protein could be a useful prognostic biomarker for HCC. Consistent with this, SPON2 protein expression level and tumor thrombus correlated with OS in univariate analysis and were independent predictors of poorer OS in multivariate analysis.

One limitation of our study is that it was a retrospective observational study; thus, the results may not be representative of other HCC populations. Zhang et al.^[@bibr8-0300060518803232]^ reported that increased SPON2 expression in HCC patients was predictive of good survival. They speculated that SPON2 could prevent HCC progression by suppressing metastasis and facilitating M1-like macrophage recruitment to the tumor microenvironment. In contrast, Schmid et al.^[@bibr10-0300060518803232]^ found that SPON2 expression induced liver metastasis in xenografted mice. Therefore, the results of the current study must be verified in prospective studies with larger patient cohorts. Analysis of SuperPaths (<http://pathcards.genecards.org>) suggests that SPON2 may interact with various cellular pathways, such as the ERK, Rho Family GTPase, and MAPK signaling pathways (Jaccard similarity scores of 0.61, 0.61, and 0.58, respectively). It will be particularly useful to investigate whether and how these pathways might play a role in regulating SPON2 expression and function in HCC.

In conclusion, this study indicated that upregulated expression of SPON2 protein in HCC tissues is significantly correlated with reduced OS and DFS following curative resection. Measurement of the SPON2 protein level in tumor tissue may therefore be a valuable prognostic indicator for HCC.
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